Form 4: Ionis Pharmaceuticals Director Joseph Klein III Receives 2025 Equity Compensation

Ionis Pharmaceuticals Director Joseph Klein III was granted 11,518 non-qualified stock options and 5,220 restricted stock units as part of his 2025 equity compensation, adhering to the company's compensation policy.

Summary

• Joseph Klein III, a Director at Ionis Pharmaceuticals Inc. (IONS), received equity compensation on July 1, 2025.
• The compensation included a grant of 11,518 non-qualified stock options with an exercise price of $39.94 per share.
• Additionally, 5,220 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These grants were adjusted to ensure that the non-employee Director's total annual equity compensation for 2025 does not exceed $450,000, based on the aggregate grant date fair value determined in accordance with FASB Topic ASC 718.
• Both the stock options and RSUs vest 100% on the earlier of the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders.
• The stock options have an expiration date of June 30, 2035.
• The Restricted Stock Units will be delivered to the reporting person on July 15th following their vesting date.

Sentiment

Score: 5

Explanation: The document reports a routine grant of equity compensation to a director, which is a standard corporate governance practice and does not inherently indicate positive or negative sentiment regarding company performance or future prospects.

Positives

• The grant of equity compensation to Director Joseph Klein III aligns his interests with those of shareholders, incentivizing long-term company performance.
• The compensation is structured under a defined policy, indicating clear corporate governance regarding director remuneration.

Future Outlook

This document primarily reports on a past compensation grant and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

The grant of equity compensation, including stock options and restricted stock units, to non-employee directors is a standard practice across the biotechnology and pharmaceutical industries. This approach is widely used to attract and retain experienced board members and align their financial interests with the long-term success of the company.

Comparison to Industry Standards

• The equity compensation structure, including the grant of stock options and restricted stock units, is a common practice for non-employee directors in publicly traded biotechnology and pharmaceutical companies.
• While specific comparable company compensation figures are not detailed in this filing, the overall approach aligns with general industry standards for attracting and retaining qualified board members.

Corporate Governance

Related Party Transactions

• Grant of 11,518 non-qualified stock options and 5,220 Restricted Stock Units to Joseph Klein III, a director of Ionis Pharmaceuticals, as part of his routine compensation package.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's financial interests with long-term shareholder value creation.
• Management: Reflects adherence to established compensation policies for non-employee directors.

Next Steps

• Vesting of stock options and Restricted Stock Units on the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders, whichever is earlier.
• Delivery of Restricted Stock Units to the reporting person on July 15th following their vesting date.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Joseph Klein III, SEC Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock Units, Director Compensation, Corporate Governance